News | November 05, 2010

Final Patient Enrolled for PAD Study

November 5, 2010 – The final patient has been enrolled in a trial studying a balloon-expandable covered stent for those with occlusive disease of the iliac artery. The iCARUS trial is investigating the iCast stent, made by Atrium Medical.

Iliac artery occlusive disease is one form of peripheral arterial disease (PAD). Patients with PAD typically have intermittent upper and lower leg pain, commonly known as “claudication” or “rest pain.” Lower extremity leg pain is often caused by decreased blood flow due to a narrowing or thrombotic occlusion of peripheral blood vessels. It can also be a result of atherosclerosis along the luminal walls of leg arteries, including the common iliac, external iliac, femoral and popliteal vessels.

In the study, the stent is used to re-open diseased iliac arteries, which feed blood flow to the legs from the aorta.

“I am thrilled that we have completed enrollment in the iCARUS trial,” said John R. Laird, M.D., U.C. Davis vascular center in Sacramento, Calif., and principal investigator of the study. “This is an important study that will help define the role of the iCast covered stent for the treatment of iliac occlusive disease.”

The iCast balloon-expandable covered stent is a micro-thin biomaterial film encapsulating a stainless steel slotted tube stent. Since it is pre-mounted by the company onto a balloon delivery catheter, it offers single-operator deployment through a very small diameter introducer sheath, without the need for surgery. The delivery system is compatible with 0.035-inch guidewires.

The stent is currently an investigational device in the United States and is currently FDA-approved for treating tracheobronchial strictures.

For more information: www.atriummed.com.

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init